TLON receives Marqibo SPA. BNVI Menerba update tmrw + QLTI

Aug 29, 2011 No Comments by

Bionovo, Inc. (NASDAQ: BNVI) announced today that it will host a conference call on Tuesday, August 30, 2011, to discuss the results of the completed Tolerability Trial of its drug candidate for menopausal hot flashes, Menerba, at 2:00 p.m. Pacific Time. It will also discuss its overall clinical development plan and the impending Phase 3 study scheduled to start shortly.

QLT Inc. (Nasdaq:QLTI) (TSX:QLT) today announced results of its Phase 2 clinical study on the efficacy and safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in subjects with ocular hypertension (OH) and open-angle glaucoma (OAG). The primary endpoint was the mean change in IOP from baseline (measured as mmHg) at 2 weeks. After 2 weeks of L-PPDS treatment, IOP showed a statistically significant mean change from baseline of -6.2 mmHg (95% C.I. -6.8, -5.6). At the end of 2 weeks, 73% of subjects showed an IOP reduction vs. baseline of 5 mmHg or greater and 51% of subjects showed a reduction of 6 mmHg or greater. The mean percentage change in IOP from baseline at 2 weeks was -24.3%, which was statistically significant (95% C.I. -26.7, -21.9).

Talon Therapeutics, Inc., (OTCBB:TLON), announced today it has reached agreement with FDA regarding a special protocol assessment (SPA) for its planned Phase 3 study of Marqibo in adults with newly diagnosed Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL).Talon submitted a NDA to the FDA in July 2011 seeking accelerated approval of Marqibo in adult Ph- ALL, in second or greater relapse or that has progressed following two or more prior lines of anti-leukemia therapy. The Phase 3 study now under SPA, named HALLMARQ (Halting newly diagnosed Adult acute Lymphoblastic Leukemia with Marqibo containing chemotherapy), is intended to be a confirmatory study to be completed following the accelerated approval of Marqibo. Talon expects to know if the NDA has been accepted for filing by the FDA in mid-September 2011.

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “TLON receives Marqibo SPA. BNVI Menerba update tmrw + QLTI”

Leave a Reply